{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:09:24Z","timestamp":1779905364735,"version":"3.53.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:33:50Z","timestamp":1725276830000},"page":"709-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biologics in Asthma"],"prefix":"10.1016","volume":"44","author":[{"given":"Gabriel","family":"Lavoie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.iac.2024.08.003_bib1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9842","key":"10.1016\/j.iac.2024.08.003_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2024.08.003_bib4","series-title":"BEST (biomarkers, EndpointS, and other tools) resource","year":"2016"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0032-2016","article-title":"Paul Ehrlich and the early history of granulocytes","volume":"4","author":"Kay","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.iac.2024.08.003_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/archinte.1922.00110120002001","article-title":"The pathology of bronchial asthma","volume":"30","author":"Huber","year":"1922","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.iac.2024.08.003_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2024.08.003_bib8","doi-asserted-by":"crossref","unstructured":"Zeiger RS, Schatz M, Dalal AA, et\u00a0al. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study. J Allergy Clin Immunol Pract: 2017:5(1):144-153.e8.","DOI":"10.1016\/j.jaip.2016.07.015"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0006-291X(91)91268-H","article-title":"Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans","volume":"181","author":"Gustafsson","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2024.08.003_bib11","first-page":"36","article-title":"Predictive value of exhaled nitric oxide in the management of asthma: a systematic review","volume":"92","author":"Lehtim\u00e4ki","year":"2024","journal-title":"Adv Respir Med"},{"issue":"8","key":"10.1016\/j.iac.2024.08.003_bib12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/cea.13137","article-title":"Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12","volume":"48","author":"Mogensen","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2024.08.003_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101533","article-title":"Diagnostic accuracy of FeNO in asthma and predictive value for inhaled corticosteroid responsiveness: A prospective, multicentre study","volume":"50","author":"Schneider","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib14","article-title":"Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis","volume":"55","author":"Kay","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM198902023200502","article-title":"Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to Allergens","volume":"320","author":"Burrows","year":"1989","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Antoine","year":"2016","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.iac.2024.08.003_bib18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2024.08.003_bib19","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"13","author":"Kim","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.003_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","article-title":"Eosinophil trafficking in allergy and asthma","volume":"119","author":"Rosenberg","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.iac.2024.08.003_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/stem.5530080713","article-title":"The biological role of interleukin 5","volume":"8","author":"Sanderson","year":"1990","journal-title":"Int J Cell Cloning"},{"issue":"12","key":"10.1016\/j.iac.2024.08.003_bib23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/cea.12156","article-title":"The relationship between eosinophilia and airway remodelling in mild asthma","volume":"43","author":"Wilson","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/019021400269943","article-title":"Bronchial casts of human lungs using negative pressure injection","volume":"26","author":"Perry","year":"2000","journal-title":"Exp Lung Res"},{"issue":"Suppl 3","key":"10.1016\/j.iac.2024.08.003_bib25","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1513\/AnnalsATS.201807-485AW","article-title":"Autopsy and imaging studies of mucus in asthma. lessons learned about disease mechanisms and the role of mucus in airflow obstruction","volume":"15","author":"Dunican","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.iac.2024.08.003_bib26","doi-asserted-by":"crossref","first-page":"156091","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.iac.2024.08.003_bib27","article-title":"Interleukin-13 in asthma and other eosinophilic disorders","volume":"4","author":"Doran","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.iac.2024.08.003_bib28","article-title":"Airway mucus and asthma: the role of MUC5AC and MUC5B. LID","author":"Bonser","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.iac.2024.08.003_bib29","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.iac.2024.08.003_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cyto.2015.05.019","article-title":"Mast cell production and response to IL-4 and IL-13","volume":"75","author":"McLeod","year":"2015","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib34","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Timothy","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.iac.2024.08.003_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1378\/chest.129.3.565","article-title":"Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients","volume":"129","author":"Bacci","year":"2006","journal-title":"Chest"},{"issue":"9347","key":"10.1016\/j.iac.2024.08.003_bib36","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"issue":"9171","key":"10.1016\/j.iac.2024.08.003_bib37","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"10095","key":"10.1016\/j.iac.2024.08.003_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","article-title":"Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects","volume":"132","author":"Hastie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0091-6749(97)70082-4","article-title":"Measuring airway inflammation in asthma: Eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood","volume":"99","author":"Pizzichini","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2024.08.003_bib43","first-page":"CD005603","article-title":"Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults","volume":"8","author":"Petsky","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13223-017-0190-0","article-title":"Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations","volume":"13","author":"Aziz-Ur-Rehman","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib45","first-page":"00560","article-title":"Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab","volume":"8","author":"Ian","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.iac.2024.08.003_bib46","doi-asserted-by":"crossref","unstructured":"Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation, Thorax, 52 (6), 498\u2013501.","DOI":"10.1136\/thx.52.6.498"},{"issue":"3","key":"10.1016\/j.iac.2024.08.003_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/pai.13403","article-title":"Blood eosinophil count as predictor of asthma exacerbation. a meta-analysis","volume":"32","author":"Mallah","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"10.1016\/j.iac.2024.08.003_bib48","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.waojou.2020.100110","article-title":"FEV1 decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort","volume":"13","author":"Backman","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.iac.2024.08.003_bib49","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccm.2018.10.010","article-title":"Asthma and corticosteroid responses in childhood and adult asthma","volume":"40","author":"Ramadan","year":"2019","journal-title":"Clin Chest Med"},{"issue":"7","key":"10.1016\/j.iac.2024.08.003_bib51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.iac.2024.08.003_bib52","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10039","key":"10.1016\/j.iac.2024.08.003_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.iac.2024.08.003_bib56","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/02770903.2018.1545857","article-title":"Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy","volume":"57","author":"Yang","year":"2020","journal-title":"J\u00a0Asthma"},{"issue":"8","key":"10.1016\/j.iac.2024.08.003_bib58","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.iac.2024.08.003_bib59","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/thx.2009.124925","article-title":"Exhaled nitric oxide thresholds associated with a sputum eosinophil count \u22653% in a cohort of unselected patients with asthma","volume":"65","author":"Schleich","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.iac.2024.08.003_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib61","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1164\/rccm.202109-2093ST","article-title":"Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official american thoracic society clinical practice guideline","volume":"204","author":"Khatri","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2024.08.003_bib62","unstructured":"Excellence. NIfHaC. Asthma: diagnosis, monitoring and chronic asthma management 2017;NG80."},{"key":"10.1016\/j.iac.2024.08.003_bib63","unstructured":"Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention, 2023. GINA guidelines 2023."},{"issue":"8","key":"10.1016\/j.iac.2024.08.003_bib64","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/cea.14359","article-title":"Effectiveness of FeNO-guided treatment in adult asthma patients: a systematic review and meta-analysis","volume":"53","author":"Korevaar","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"10.1016\/j.iac.2024.08.003_bib65","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201204-0587OC","article-title":"The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma","volume":"186","author":"McNicholl","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib66","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib67","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib68","doi-asserted-by":"crossref","first-page":"AB189","DOI":"10.1016\/j.jaci.2021.12.624","article-title":"The impact of baseline exhaled nitric oxide levels and blood eosinophil count on clinical outcomes in REALITI-A","volume":"149","author":"Bernstein","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib69","first-page":"349","article-title":"Type-2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"Yunus","year":"2024","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib70","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.waojou.2021.100544","article-title":"Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status","volume":"14","author":"Nerpin","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"10423","key":"10.1016\/j.iac.2024.08.003_bib71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5578\/tt.20239904","article-title":"Can omalizumab be an alternative treatment for non-atopic severe asthma? a real-life experience with omalizumab","volume":"71","author":"Ediger","year":"2023","journal-title":"Tuberk Toraks"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/aei.v50i5.594","article-title":"The efficacy of omalizumab treatment in patients with nonatopic severe asthma","volume":"50","author":"Atayik","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"10.1016\/j.iac.2024.08.003_bib74","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.iac.2024.08.003_bib75","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib76","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib77","doi-asserted-by":"crossref","first-page":"AB191","DOI":"10.1016\/j.jaci.2021.12.628","article-title":"Influence of baseline total IgE and history of previous omalizumab use on the impact of mepolizumab in reducing rate of severe asthma exacerbations: results from the real-world REALITI-A study","volume":"149","author":"Lee","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib78","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib79","first-page":"679","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","article-title":"Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps","volume":"64","author":"Tiotiu","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.iac.2024.08.003_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/resp.14578","article-title":"Benralizumab and Mepolizumab treatment outcomes in two severe asthma clinics","author":"Langton","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.iac.2024.08.003_bib82","doi-asserted-by":"crossref","first-page":"9230234","DOI":"10.1155\/2018\/9230234","article-title":"Neutrophilic asthma is associated with increased airway bacterial burden and disordered community composition","volume":"2018","author":"Yang","year":"2018","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.iac.2024.08.003_bib83","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/all.15375","article-title":"Nontypeable Haemophilus influenzae infection of pulmonary macrophages drives neutrophilic inflammation in severe asthma","volume":"77","author":"Ackland","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2024.08.003_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02279-21","article-title":"Identifying bacterial airways infection in stable severe asthma using oxford nanopore sequencing technologies","volume":"10","author":"Jabeen","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.iac.2024.08.003_bib85","article-title":"Integrated species-level analysis of metagenome and inflammatory mediators reveals dominant and distinct roles of haemophilus influenzae and moraxella catarrhalis in severe asthma","author":"Jabeen","year":"2023","journal-title":"SSRN Preprint"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib86","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.mucimm.2023.07.002","article-title":"IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma","volume":"16","author":"Curren","year":"2023","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.08.003_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1465-9921-14-8","article-title":"Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses","volume":"14","author":"Koga","year":"2013","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.iac.2024.08.003_bib88","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2010.02.015","article-title":"Airway neutrophil inflammatory phenotype in older subjects with asthma","volume":"125","author":"Nyenhuis","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.iac.2024.08.003_bib89","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:59Z","timestamp":1728391199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000602"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.003","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}